[HTML][HTML] C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study

…, G Zeitler, V Foris, S Mollnar, M Stotz, CH Rossmann… - Cancers, 2020 - mdpi.com
Background: Biomarkers for predicting response to immune checkpoint inhibitors (ICI) are
scarce and often lack external validation. This study provides a comprehensive investigation …

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells

…, T Kroneis, S Chen, M Smolle, C Rossmann… - Clinical …, 2018 - academic.oup.com
BACKGROUND Liquid biopsies can be used in castration-resistant prostate cancer (CRPC)
to detect androgen receptor splice variant 7 (AR-V7), a splicing product of the androgen …

[HTML][HTML] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

…, F Moik, DA Barth, CH Rossmann… - European Journal of …, 2021 - Elsevier
Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line
treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no …

The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study

…, J Mirzayeva, F Posch, C Rossmann… - Therapeutic …, 2020 - journals.sagepub.com
Aims: Line immune-assays (LIA) for the detection of myositis-specific antibodies (MSA) are
used widely for characterization of idiopathic inflammatory myopathies (IIM). Their current use …

[HTML][HTML] T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: A clinico-pathological study

…, B Prietl, M Pichler, A Gerger, C Rossmann… - British journal of …, 2021 - nature.com
Background Soft tissue sarcomas (STS) are generally considered non-immunogenic,
although specific subtypes respond to immunotherapy. Antitumour response within the tumour …

[HTML][HTML] Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients

…, V Tiran, AAN Treitler, C Suppan, C Rossmann… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Blood-based biomarkers such as circulating tumor cells (CTCs) provide dynamic real-time
assessment of molecular tumor characteristics beyond the primary tumor. The aim of this …

[HTML][HTML] Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

…, JM Riedl, T Winder, A Terbuch, CH Rossmann… - Scientific Reports, 2019 - nature.com
Whether 2 nd -line-chemotherapy (2LCTX) + best-supportive-care (BSC) benefits patients
with advanced biliary tract cancer (aBTC) more than BSC alone is unclear. We therefore …

[HTML][HTML] Benefit of metastasectomy in renal cell carcinoma: a propensity score analysis

…, DA Barth, M Seles, A Terbuch, CH Rossmann… - Clinical Genitourinary …, 2022 - Elsevier
Introduction : To quantify the magnitude of benefit of metastasectomy as compared to medical
treatment alone in patients with metastatic renal cell carcinoma (mRCC). Patients and …

Cancer stem cell gene variants in CD44 predict outcome in stage II and stage III colon cancer patients

…, M Pichler, M Smolle, J Riedl, C Rossmann… - Anticancer …, 2017 - ar.iiarjournals.org
Background/Aim: Growing evidence suggests that human cancers are stem cell diseases and
recent data support the existence of cancer stem cells (CSCs) in a variety of malignancies, …

[HTML][HTML] Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an …

…, J Szkandera, MA Smolle, T Winder, CH Rossmann… - BMC cancer, 2017 - Springer
Background Venous thromoboembolism (VTE) is a frequent and burdensome complication
of metastatic colorectal cancer (CRC). However, the epidemiology of VTE in patients with …